XNAS · Healthcare · Biotechnology
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Molecular Partners delivered a weak Q2, missing EPS by **$0.43** as the biotech continued to burn cash with no revenue reported. With no fresh catalyst or guidance, this looks like a straightforward setback rather than a thesis-changing event.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-25 | Q2 2026 | -0.45 | -0.89 | -96.67% | $0 | ❌ Miss | -1.14% | -2.17% | — |
| 2026-05-12 | Q1 2026 | -0.38 | -0.45 | -17.37% | $0 | ❌ Miss | +0.00% | -7.43% | -8.17% |
| 2026-03-12 |
| Q4 2025 |
| -0.38 |
| -0.41 |
| -7.89% |
| $0 |
| ❌ Miss |
| +0.00% |
| -0.43% |
| -8.03% |
| 2025-10-30 | Q3 2025 | -0.46 | -1.65 | -258.70% | $0 | ❌ Miss | — | — | — |
| 2025-08-25 | Q2 2025 | -0.53 | -0.67 | -26.42% | $0 | ❌ Miss | -13.39% | -9.85% | -12.69% |
| 2025-03-06 | FY 2024 | — | -1.81 | — | $5.6M | — | +2.24% | -10.41% | -27.76% |
| 2024-08-26 | H1 2024 | — | -0.89 | — | $4.8M | — | +11.79% | -8.89% | -25.36% |
| 2024-03-14 | FY 2023 | — | -2.13 | — | $7.9M | — | — | — | — |
Showing last 8 quarters.